Sanofi-Aventis Suspends Phase III Acomplia Trial in Japan
This article was originally published in PharmAsia News
Executive Summary
Sanofi Aventis announced Nov. 6 that the company decided to halt all clinical trials for obesity drug Acomplia (rimonabant) in compliance with European Medicines Agency's recommendation. The company has three ongoing Phase III trials in Europe and one in Japan for rimonabant. The company suspended marketing the drug in 18 European countries Oct. 23 due to the EMEA's recommendation. The agency cited mental disorder risks. Rimonabant is currently sold in 14 countries outside Europe. (Click here for more - Japanese language